Jill Lacy MD

Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program

Medical Oncology

Education & Training

  • M.D., Yale University (1978)
  • Resident, Yale University School of Medicine , Internal Medicine (1979 - 1982)
  • Fellow, Yale University School of Medicine , Oncology (1982 - 1985)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Colorectal cancer; pancreatic cancer; esophageal cancer; gastric cancer; gall bladder cancer; anal cancer; biliary cancer; liver cancer; neuroendocrine tumors; brain tumors; non-Hodgkin's lymphoma (NHL); Hodgkin's disease; Kaposi's sarcoma


Cancers Treated

Anal, Brain, Colon (including Rectum), Esophagus, Gall Bladder, Gastrointestinal (including Stomach), Kaposi's Sarcoma, Pancreas, Unknown primary


Board Certifications

  • Internal Medicine, Board Certified (1982)
  • Medical Oncology, Board Certified (1991)

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonC80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Stage IB Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, and EsophagusRTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma {CIRB}
Colon Cancer and Colon19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the colon
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, Esophagus, and StomachA RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Colon, Lung, and RectumA PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS

More Clinical Trials...

Edit Profile